Viking Therapeutics VKTX Unpaid Deferred Initial Public Offering And Other Financing Costs
Unpaid Deferred Initial Public Offering And Other Financing Costs at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept vktx:UnpaidDeferredInitialPublicOfferingAndOtherFinancingCosts.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's unpaid deferred initial public offering and other financing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's unpaid deferred initial public offering and other financing costs?
- Viking Therapeutics (VKTX) reported unpaid deferred initial public offering and other financing costs of $50K in Q1 2026.
- How has Viking Therapeutics's unpaid deferred initial public offering and other financing costs changed year-over-year?
- Viking Therapeutics's unpaid deferred initial public offering and other financing costs decreased by 0.0% year-over-year, from $50K to $50K.
- What does unpaid deferred initial public offering and other financing costs mean?
- This represents costs associated with an initial public offering or other financing activities that have been incurred but not yet paid in cash. It acts as a bridge between accrual-based accounting and cash flow reporting. Monitoring these liabilities is important for understanding near-term cash outflows related to past financing events.